Guy’s & St Thomas’ NHS Foundation Trust

UK based diagnostics technology company Testcard will unveil their non-invasive diagnostic solutions at MEDICA 2023 designed to make testing more accessible for consumers and in clinical settings. As a participant in the ABHI UK Pavilion, Testcard will highlight its technology that transforms a mobile device into a clinical-grade scanner, "revolutionising" the field of diagnostics. At MEDICA 2023, the company will showcase its three primary areas of focus. This includes their revolutionary at-home UTI test kit, boasting accuracy comparable to urine tests performed in clinical settings. When coupled with the smartphone app, it allows users to obtain immediate accurate test results from the comfort of their own home. The technology directly integrates with individual suppliers to maintain a complete end-to-end pathway, back to the supplier for treatment. Testcard has also developed advanced technical solutions for patient screening, helping identify individuals at risk of serious illnesses. By streamlining the process and enabling at-risk patients to test at home, healthcare providers can promptly allocate resources to those in need, optimising GP and laboratory time. In collaboration with Guys & St Thomas NHS Foundation Trust (GSTT), the company has launched the revolutionary ClearScreen technology that digitalises point of care rapid diagnostic testing including lateral flow tests. The ClearScreen app immediately records patients’ test results digitally and transmits them to the electronic patient record (EPR) in seconds, meaning the result is available to all clinical teams in real time. Testcard's expanding test portfolio includes Single Covid, Covid/Flu dual test, Covid/Flu/RSV Triple test, Single RSV, Pregnancy, Strep A, CRP, D-Dimer, Troponin, and Monkeypox, contributing to quicker, more efficient healthcare pathways. TestCard’s chief scientific officer Dr. Andrew Botham said: “Rapid diagnostic testing helps to ease the pressures on health systems. Test results can be generated sooner and acted upon immediately, while mitigating risk for everyone. It also improves the patient pathway with a more effective patient triage, reducing delays with test results. Testcard is excited to be joining ABHI at MEDICA 2023 to showcase our cutting-edge range of technologies designed to transform the fast-growing field of diagnostics, and we look forward to connecting with partners in the region.” Testcard's platform technology reduces the need for traditional testing, reducing the hassle of multiple appointments, lengthy wait times, and lab fees. The focus on immediacy and accessibility empowers users to receive accurate test results at home or in clinical settings while seamlessly integrating into electronic patient record systems for effective treatment. In the last year, TestCard has signed a major partnership agreement with Roche Diagnostics, one of the biggest global diagnostics companies. Their technology has also garnered recognition, with TestCard winning multiple awards, including the Digital Health Award, the Shift.ms Digital Award, and the Royal Society of Chemistry Emerging Technologies Competition. TestCard is a platform technology currently in partnership with Superdrug, the NHS and Roche Diagnostics that is revolutionising healthcare by increasing the accessibility and diagnostic capability of non-invasive testing. MEDICA is taking place from 13-16 November 2023 in Messe Düsseldorf, Germany. To discover more about Testcard and explore the benefits of partnership, visit their booth at the ABHI UK Pavilion - Hall 16 Stand 16J60.5.

HENDERSON, Nev., Oct. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report summarising key themes from its recent Key Opinion Leader ("KOL") roundtable on sepsis management. Remi Rabeuf, Lifecycle Leader at Volition, said: "We were delighted to bring together some of the world's leading experts in sepsis to explore the potential of using Volition's Nu.Q® NETs technology effectively in clinical practice. The panel discussed how Nu.Q® NETs could be used to enhance the management and outcome of sepsis patients and its potential application in early diagnosis, treatment guidance, treatment monitoring, and personalized medicine. The KOLs also discussed areas for future research." The roundtable was chaired by Professor Djillali Annane, Professor of Medicine at University Paris Saclay-UVSQ and University Versailles SQY, and comprised: Professor Evangelos J. Giamarellos-Bourboulis, National and Kapodistrian University of Athens, Greece and Chair of the European Sepsis Alliance. Professor Mervyn Singer, University College London, UK. Co-chair of the Sepsis-3 Definitions International Task Force; past-chair, International Sepsis Forum; Sepsis Topic Adviser to NICE; Emeritus NIHR Senior Investigator. Professor Adrienne Randolph, Professor of Anaesthesia and Paediatrics at Harvard Medical School, Paediatric Critical Care Physician at Boston Children's Hospital, U.S. and Chair of the International Sepsis Forum. Dr Tanya Novak, PhD Scientist at Boston Children's Hospital and an instructor at Harvard Medical School, U.S. Professor Michael Bauer, Professor and Chair of the Department of Anaesthesiology and Intensive Care Medicine at Jena University Hospital, Germany. Professor Guillaume Monneret, Professor of Immunology at Hospices Civils de Lyon, France. Professor Lea Payen, Professor in Molecular Biology and Toxicology at the University of Lyon I and Hospices Civils de Lyon, France. Dr Andrew Aswani, Consultant in Intensive Care Medicine and Anaesthesia at Guy's and St Thomas' Hospital in London, UK and Co-founder and Chief Medical Officer of Santersus AG. Dr Andrew Retter, Consultant in Intensive Care Medicine at Guys and St Thomas' Hospital in London, UK and a Medical Consultant to Volition. Read the full KOL Meeting report ' Sepsis: hope of a brighter future' here. Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's technology go to: . About Volition Volition is a multi-national epigenetics company powered by Nu.Q®, its proprietary nucleosome quantification platform. Through its subsidiaries, Volition is developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore. For more information about Volition's Nu.Q® technology go to: The contents found at the Volition website address are not incorporated by reference into this document and should not be considered part of this document. The website address is included in this document as an inactive textual reference only. Media Enquiries: Louise Batchelor/Debra Daglish, Volition, [email protected] +44 (0)7557 774620 Safe Harbor Statement Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to the timing and launch of product sales, and the potential uses, benefits and effectiveness of its Nucleosomics™ technology platform, including the Nu.Q® NETs test. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests, a failure by the marketplace to accept Volition's, Nu.Q® NETs test or other products based on its Nucleosomics™ platform; Volition's failure to secure adequate intellectual property protection; Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition will face fierce competition and its intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Forward-looking statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. SOURCE VolitionRx Limited

LONDON--( BUSINESS WIRE )--The UK Focused Ultrasound Foundation (UK FUSF), dedicated to advancing the development and adoption of focused ultrasound in the UK, today announced its formal launch. Focused ultrasound is a groundbreaking platform technology that uses ultrasound energy guided by real-time imaging to treat tissue deep in the body, without incisions or radiation. The Foundation will celebrate its launch with an event being held on 31 January at the House of Lords with important guests including MPs, members of the House of Lords, business leaders, and experts from medical charities and some of the UK’s leading research institutions, including the Institute of Cancer Research, Oxford University, and Imperial, King’s and University Colleges, London. Currently, focused ultrasound treatment for both prostate cancer and essential tremor has National Institute for Health and Care Excellence (NICE) approval and National Health Service England (NHS) coverage. 1,2 The technology has 32 regulatory approvals worldwide and is in various stages of research and development for nearly 170 diseases and conditions including Alzheimer’s disease, Parkinson’s disease, metastatic breast tumours, and tumours of the brain, liver, pancreas, and prostate. Launch of the UK FUSF will help enable donations to be applied directly to laboratory research and clinical trials in the UK, accelerating and expanding the exceptional work that has been ongoing for several years. It is hoped this will significantly increase the accessibility to already approved focused ultrasound-based treatments, which currently have limited availability in the UK. Specific areas of focus for the UK FUSF include cancer immunotherapy, brain diseases, pancreatic cancer, prostate cancer, and pediatric applications. “ Our vision at the Foundation is for focused ultrasound to be used in the UK to improve the lives of millions of people afflicted with a wide variety of serious medical disorders in the shortest time possible,” said Foundation Chairman Philip Keevil. “ By identifying opportunities, inspiring collaboration, raising awareness and overcoming barriers, the Foundation will shorten the time from laboratory research to widespread treatment using this remarkable and versatile technology.” The UK FUSF is an independent charity registered with the Charity Commission and HMRC, and GiftAid Eligible. It works closely with, but is independent of, the US-based Focused Ultrasound Foundation, aligning on goals and resources to advance focused ultrasound to treat millions worldwide. The Institute of Cancer Research in the UK was selected in 2013 by the US organization as the second global Focused Ultrasound “Center of Excellence” (there are now only 10 worldwide). UK FUSF is already partnering with the prostate cancer charity Prost8 UK and focused ultrasound device manufacturer Sonablate to increase access of focused ultrasound treatment for patients diagnosed with prostate cancer by co-funding the deployment early this year of a new prostate cancer treatment device at Guys & St Thomas' Hospital in London. “ I’ve been studying the use of focused ultrasound technology in oncology and have worked with the US Foundation for many years,” said Professor Gail ter Haar of The Institute of Cancer Research. “ The launch of the UK FUSF is an incredibly important milestone. This organisation will further catalyse development and adoption of the technology, bringing much needed innovative new treatments to our community and beyond.” The potential of focused ultrasound to be a game-changing treatment for so many diseases has attracted the attention of celebrities including musician Peter Gabriel, an honorary member of the UK FUSF Advisory Council. Said Mr. Gabriel, “ Sound has been the stuff I work with every day of my life. It’s thrilling to see how powerful it can be when ingeniously applied to healthcare. I’m delighted to see these pioneering technologies take root in the UK.” About the UK Focused Ultrasound Foundation Together with our sister organisation in the US, the UK Focused Ultrasound Foundation is working to provide patients with this noninvasive, life-changing treatment option in the shortest time possible. The UK FUSF will contribute financial and human resources to foster collaboration, to build knowledge and to streamline the process and overcome barriers. Focused ultrasound research in the UK has been funded by the US Foundation since 2009. For more information visit https://ukfusf.org/ . About Focused Ultrasound Focused ultrasound uses ultrasound energy guided by real-time imaging to treat tissue deep in the body without incisions or radiation. It is approved in the UK to treat prostate cancer and essential tremor. Dozens of additional indications are approved elsewhere in the world, including the United States, Europe and Asia. The technology is in various stages of research and development for nearly 170 diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, metastatic breast tumours, and tumours of the brain, liver and pancreas. Click here to watch a 6-minute video about focused ultrasound in the UK. References 1.National Institute for Health and Care Excellence 2005. High-intensity focused ultrasound for prostate cancer. Interventional procedures guidance [IPG118] . Available at: https://www.nice.org.uk/guidance/ipg118/chapter/1-Guidance . Last accessed January 2023. 2. National Institute for Health and Care Excellence 2018. Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor. Interventional procedures guidance [IPG617] . Available at: https://www.nice.org.uk/guidance/ipg617/chapter/1-Recommendations . Last accessed January 2023.